Obiltoxaximab - Elusys Therapeutics

Drug Profile

Obiltoxaximab - Elusys Therapeutics

Alternative Names: Anthim; ETI-204

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elusys Therapeutics
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anthrax

Most Recent Events

  • 28 Nov 2017 Obiltoxaximab is still in phase I trials for Anthrax (In volunteers) in USA (IM)
  • 28 Nov 2017 Launched for Anthrax (Combination therapy) in USA (IV) before November 2017 (Elusys Therapeutics website, November 2017)
  • 28 Nov 2017 Launched for Anthrax (Prevention) in USA (IV) before November 2017 (Elusys Therapeutics website, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top